Compare Tango Therapeutics Inc. (TNGX) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Vanguard High Dividend Yield ETF — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B), while Vanguard High Dividend Yield ETF trades at $159.6 (market cap $100.80B). The key difference: Vanguard High Dividend Yield ETF is far larger — about 27× Tango Therapeutics Inc.'s market cap, and Vanguard High Dividend Yield ETF is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Vanguard High Dividend Yield ETF for 140 Days on average.
| TNGX | VYM | |
|---|---|---|
Market Cap | $3.74B | $100.80B |
Volume | 3,438,781 | 1,062,392 |
Sector | Health | — |
52-Week High | $32.90 | $167.03 |
52-Week Low | $7.50 | $138.43 |
Typical Hold Time | 0 Days | 140 Days |
Enterprise Value | $2.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
VYM trades at $159.11, down slightly by 0.08% on the day. The ETF shows a bullish technical signal overall, with moving averages supporting an uptrend, though oscillators are neutral. Recent news highlights its consistent dividend yield of 2.42% but questions its performance versus peers like SCHD and IDV. Key support sits at $158, with resistance at $160.
The outlook for VYM hinges on its dividend reliability amid competition from higher-yielding or better-performing ETFs. Risks include exposure to dividend cuts in holdings like Intel and Walgreens. Analyst sentiment is mixed, favoring a hold rating due to moderate returns compared to alternatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
